Clinical Trial Update: PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial of PG2 given intravenously in patients with advanced cancer has completed Phase I/II evaluation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• PG2

Snippet

Sponsor: PhytoHealth Corporation | Conditions: Neoplasm Metastasis, Neoplasm Recurrence | Phase 1, Phase 2 | Status: COMPLETED